Recombinant Equine Herpesvirus-1 Vaccine Containing Mutated Glycoprotein C and Uses Thereof

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent introduces a novel vaccine for equine herpesvirus-1 (EHV-1) based on a genetically engineered (recombinant) EHV-1 virus with a mutated (non-functional or deleted) glycoprotein C (gC) gene. The modification renders the virus attenuated (weakened) and safe for use as a live vaccine, while still triggering an immune response in animals—most notably horses—to protect against EHV-1 infection and related diseases.

Use CasesContent extracted from patent full text and abstract with AI.

• Vaccination of horses and other equines to prevent EHV-1 respiratory disease, abortion, or neurological disease.
• Use in managing and preventing EHV-1 outbreaks in breeding farms, racetracks, and stables.
• Vaccination programs for zoo or wild equines (e.g., zebras or donkeys) susceptible to EHV-1.
• Development of veterinary vaccination kits integrating this recombinant vaccine for field use.
• Possibility of adapting the technology for other veterinary herpesvirus vaccines after further research.

BenefitsContent extracted from patent full text and abstract with AI.

• Provides stronger protection than conventional inactivated (killed) EHV-1 vaccines by eliciting robust immune responses, including both antibody and cell-mediated immunity.
• The attenuated virus is much less likely to cause disease or undesirable side effects.
• Reduces virus shedding and viremia after challenge, lowering risk of outbreak transmission.
• Demonstrated safety and efficacy in both horse and mouse models; vaccination does not induce significant disease symptoms.
• Can be incorporated into diverse vaccination regimens, including prime-boost strategies, for optimal protection.
• Potential to decrease economic losses associated with equine herpesvirus outbreaks.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention provides compositions or vaccines that contain a recombinant EHV-1 that elicit an immune response in animals against equine herpesvirus, including compositions comprising said recombinant EHV-1, methods of vaccination against equine herpesvirus, and kits for use with such methods and compositions.